AnaptysBio, Inc.
NASDAQ:ANABBiotechnology
-$1.07 today
- Market cap
- $1.40B
- Beta
- 0.41
- P/E (TTM)
- -59.7
- EPS (TTM)
- -$0.93
Volume 0.57M
Average 0.76M
ANAB Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
AnaptysBio, Inc.NASDAQ: ANAB
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $33.86M fell 17.8% year over year, ahead of the -23.4% change in trailing-twelve-month research & development. Sequentially, it rose 32.5% from the prior quarter. Over 3 fiscal years it compounded at +15.3% a year.
Context
- Research & development amounted to 58.0% of revenue in FY2025, down 121.5 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of -17.8% holds above the trailing-twelve-month pace of -23.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 135.97M USD
- Year-over-year change
- -17.0%
- 4-year CAGR
- +8.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 135.97M | -17.0% |
| FY2024 | 2024-12-31 | 163.84M | +17.3% |
| FY2023 | 2023-12-31 | 139.62M | +57.2% |
| FY2022 | 2022-12-31 | 88.8M | -9.8% |
| FY2021 | 2021-12-31 | 98.5M | — |
Research & Development vs competitors
How ANAB compares with its peers on the latest reported figures
- ANAB's LTM Mar 2026 research & development of $128.65M is the 6th highest of the 10 companies compared; the peer median is $172.31M.
- Its year-over-year change of -23.4% is the 9th highest of 10, against a peer median of +27.7%.
- Research & development amounts to 55.4% of revenue for ANAB, versus a peer median of 3643.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M | +16.2% | +41.8% | 6608.2% | |
| LTM Jun 2026 | $255.77M | +11.4% | +6.3% | 243.6% | |
| LTM Mar 2026 | $220.82M | +62.1% | +69.0% | — | |
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
| LTM Mar 2026 | $172.31M | +17.5% | +18.0% | — | |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $71.8M | +27.7% | +16.5% | — |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| FY2025 | $37.8M | +29.2% | -26.9% | 59059.4% | |
| LTM Mar 2026 | $15.25M | -66.4% | -18.8% | 28.4% | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding ANAB) | $172.31M | +27.7% | +16.5% | 3643.0% | |
Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 63.18M | 10.29M | 17.16M | 91.28M | 234.6M |
| Cost of Revenue | 98.5M | 88.8M | 132.28M | 163.84M | 2.42M |
| Gross Profit | (35.32M) | (78.51M) | (115.13M) | (72.56M) | 232.18M |
| Gross Margin | -55.9% | -763.2% | -671.0% | -79.5% | 99.0% |
| Research & Development | 98.5M | 88.8M | 139.62M | 163.84M | 135.97M |
| Selling, General & Admin | 21.49M | 36.64M | 41.95M | 42.39M | 50.74M |
| Operating Expenses | 21.49M | 36.64M | 49.29M | 42.39M | 184.28M |
| Depreciation & Amortization | 2.09M | 2.34M | 652K | 2.4M | 2.42M |
| EBITDA | (55.71M) | (105.26M) | (156.42M) | (92.74M) | 69.25M |
| EBITDA Margin | -88.2% | -1023.2% | -911.7% | -101.6% | 29.5% |
| Operating Income | (56.81M) | (115.15M) | (164.41M) | (114.95M) | 47.9M |
| Operating Margin | -89.9% | -1119.4% | -958.3% | -125.9% | 20.4% |
| Interest Income | 431K | 7.55M | 18.87M | 19.79M | 13.5M |
| Interest Expense | 1.45M | 21.11M | 18.08M | 50.09M | 79.89M |
| Other Income / Expenses | (982K) | (13.55M) | 788K | (30.28M) | (60.96M) |
| Income Before Tax | (57.8M) | (128.7M) | (163.62M) | (145.23M) | (13.07M) |
| Pre-Tax Margin | -91.5% | -1251.1% | -953.7% | -159.1% | -5.6% |
| Income Tax Expense | 0 | 24K | (4K) | 3K | 164K |
| Net Income | (57.8M) | (128.72M) | (163.62M) | (145.23M) | (13.23M) |
| Net Margin | -91.5% | -1251.3% | -953.7% | -159.1% | -5.6% |
| EPS (Basic) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| EPS (Diluted) | (2.11) | (4.57) | (6.08) | (5.12) | (0.46) |
| Weighted Avg Shares | 27.43M | 28.17M | 26.92M | 28.38M | 27.79M |
| Weighted Avg Shares (Diluted) | 27.43M | 28.17M | 26.92M | 28.38M | 31.34M |
AnaptysBio, Inc.
NASDAQ:ANAB
Intrinsic Alpha fair value
Locked
Current Price
$47.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.